176,770 Shares in Design Therapeutics, Inc. $DSGN Acquired by J. Goldman & Co LP

J. Goldman & Co LP bought a new stake in Design Therapeutics, Inc. (NASDAQ:DSGN) during the second quarter, Holdings Channel.com reports. The firm bought 176,770 shares of the company’s stock, valued at approximately $2,558,000.

A number of other large investors have also modified their holdings of DSGN. Canada Pension Plan Investment Board bought a new position in Design Therapeutics in the 2nd quarter worth about $472,000. Legal & General Group Plc acquired a new stake in Design Therapeutics in the 2nd quarter valued at approximately $43,000. Algert Global LLC raised its stake in Design Therapeutics by 44.6% during the 2nd quarter. Algert Global LLC now owns 296,085 shares of the company’s stock valued at $4,284,000 after acquiring an additional 91,346 shares in the last quarter. BlackRock Inc. bought a new stake in Design Therapeutics during the 2nd quarter valued at $38,491,000. Finally, Deutsche Bank AG acquired a new position in Design Therapeutics during the 2nd quarter worth $443,000. Institutional investors and hedge funds own 56.64% of the company’s stock.

Design Therapeutics Price Performance

DSGN stock opened at $15.68 on Wednesday. The firm has a market capitalization of $981.25 million, a P/E ratio of -13.29 and a beta of 1.63. Design Therapeutics, Inc. has a 52-week low of $4.92 and a 52-week high of $17.25. The company’s 50 day simple moving average is $13.77 and its 200-day simple moving average is $12.25.

Design Therapeutics (NASDAQ:DSGN) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.02. Sell-side analysts predict that Design Therapeutics, Inc. will post -1.41 EPS for the current fiscal year.

Analyst Ratings Changes

DSGN has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Design Therapeutics in a research note on Friday, July 17th. Piper Sandler reissued an “overweight” rating and issued a $20.00 price objective on shares of Design Therapeutics in a research note on Wednesday, April 29th. Cantor Fitzgerald initiated coverage on Design Therapeutics in a report on Tuesday, May 12th. They set an “overweight” rating on the stock. Oppenheimer raised their price objective on shares of Design Therapeutics from $18.00 to $21.00 and gave the company an “outperform” rating in a research report on Monday, May 4th. Finally, Wall Street Zen upgraded shares of Design Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Design Therapeutics has an average rating of “Moderate Buy” and an average target price of $16.50.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.